| Literature DB >> 34068616 |
Domenico Iacopetta1, Alessia Catalano2, Jessica Ceramella1, Carmela Saturnino3,4, Lara Salvagno2, Ileana Ielo5, Dario Drommi6, Elisabetta Scali7, Maria Rosaria Plutino5, Giuseppe Rosace8, Maria Stefania Sinicropi1.
Abstract
In the late 1930s and early 1940s, it was discovered that the substitution on aromatic rings of hydrogen atoms with chlorine yielded a novel chemistry of antimicrobials. However, within a few years, many of these compounds and formulations showed adverse effects, including human toxicity, ecotoxicity, and unwanted environmental persistence and bioaccumulation, quickly leading to regulatory bans and phase-outs. Among these, the triclocarban, a polychlorinated aromatic antimicrobial agent, was employed as a major ingredient of toys, clothing, food packaging materials, food industry floors, medical supplies, and especially of personal care products, such as soaps, toothpaste, and shampoo. Triclocarban has been widely used for over 50 years, but only recently some concerns were raised about its endocrine disruptive properties. In September 2016, the U.S. Food and Drug Administration banned its use in over-the-counter hand and body washes because of its toxicity. The withdrawal of triclocarban has prompted the efforts to search for new antimicrobial compounds and several analogues of triclocarban have also been studied. In this review, an examination of different facets of triclocarban and its analogues will be analyzed.Entities:
Keywords: TCC; antimicrobials; bis-arylureas; diarylureas; metabolites; triclocarban; triclocarban analogues
Year: 2021 PMID: 34068616 PMCID: PMC8126057 DOI: 10.3390/molecules26092811
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Triclocarban and triclosan.
Figure 2Glucuronide transformation products of triclocarban.
Figure 3Dechlorinated transformation products of triclocarban.
Figure 4Structures of hydroxylated TCC transformation products and their glucuronides.
Analogues of triclocarban with antibacterial activity.
|
| Flucofuron | MIC = 0.25 mg/L | Chang et al., 2016 [ |
|
| PK150 | MIC = 0.3 µM | Le et al., 2020 [ |
|
|
| MIC50 = 0.05 µg/mL | Pujol et al., 2018 [ |
|
|
| Inhibition zones = 14.0 mm | Hassan et al., 2014 [ |
|
|
| Inhibition zone = 23 mm | Sarveswari et al., 2018 [ |
|
|
| Inhibition zone = 24 mm | Sarveswari et al., 2018 [ |
|
|
| MIC = 16 µM ( | Catalano et al., 2021 [ |
|
|
| MIC = 16 µM ( | Catalano et al., 2021 [ |
|
|
| MIC = 16 µM ( | Catalano et al., 2021 [ |
|
|
| MIC = 16 µM ( | Catalano et al., 2021 [ |
|
|
| MIC = 16 µM ( | Catalano et al., 2021 [ |
|
|
| MIC = 16 µM ( | Catalano et al., 2021 [ |
Analogues of triclocarban with various activities.
|
|
| IC50 = 1.3 µM ( | Cowan et al., 2015 [ |
|
|
| IC50 = 0.2 µM (adult | Cowan et al., 2015 [ |
|
|
| IC50 = 3.6 µM (adult | Cowan et al., 2015 [ |
|
|
| IC50 = 7.0 µM (adult | Cowan et al., 2015 [ |
|
|
| IC50 = 0.15 µM ( | Wu et al., 2018 [ |
|
|
| IC50 = 2.5 µM (juvenile | Yao et al., 2016 [ |
|
|
| IC50 = 4.7 µM ( | Ingram-Sieber et al., 2014 [ |
|
|
| IC50 = 2.8 µM (juvenile | Yao et al., 2016 [ |
|
|
| C50 = 4.26 µM (antiglycating activity) | Khan et al., 2009 [ |
|
|
| IC50 = 4.26 µM (antiglycating activity) | Khan et al., 2009 [ |
|
|
| IC50 = 0.13 µM | Obukowicz et al., 1998 [ |
|
|
| IC50 = 18.4 µg/mL | Rakesh et al., 2017 [ |
|
|
| IC50 = 20.3 µg/mL | Rakesh et al., 2017 [ |
|
|
| Feng et al., 2016 [ |